Antiemetic guidelines: Are they being used?

Lancet Oncology

Volumn 6, Issue 8, 2005, Pages 622-625

  Kaiser, Rolf ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; FLUOROURACIL; METHOTREXATE; SEROTONIN RECEPTOR;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPETENCE; DRUG EFFICACY; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROGNOSIS; QUALITY OF LIFE; STANDARD; TREATMENT OUTCOME;

EID: 22944431907     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70284-9     Document Type: Note

References (40)

1. Stewart D.J. Cancer therapy, vomiting, and antiemetics Can. J. Physiol. Pharmacol. 1990 68 304-313
2. PL Andrews CJ Davis The mechanism of emesis induced by anti-cancer therapies in: Andrews PLSG eds. Emesis in anti-cancer therapy 1993 Chapman and Hall London 113-161
3. Tyers M.B. Freeman A.J. Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists Oncology 1992 49 263-268
4. Miller A.D. Leslie R.A. The area postrema and vomiting Front Neuroendocrinol. 1994 15 301-320
5. Gregory R.E. Ettinger D.S. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: A comparison of their pharmacology and clinical efficacy Drugs 1998 55 173-189
6. Hesketh P.J van Belle S. Aapro M. et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists Eur. J. Cancer 2003 8 1074-1080
7. Gralla R.J. Itri L.M. Pisko S.E. et al. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting N. Engl. J. Med. 1981 305 905-909
8. Cunningham D. Hawthorn J. Pople A. et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5 HT3 receptor antagonist Lancet 1987 1 1461-1463
9. Hesketh P. Navari R. Grote T. et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer J. Clin. Oncol. 1996 14 2242-2249
10. Navari R.M. Kaplan H.G. Gralla R.J. et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin J. Clin. Oncol. 1994 12 2204-2210
11. Poli-Bigelli S. Rodrigues-Pereira J. Carides A.D. et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 2003 97 3090-3098
12. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of Perugia Consensus Conference Ann Oncol 9 1998 811-819
13. Gralla R.J. Roila F. Tonato M. et al. The 2004 Perugia Antiemetic Consensus Guideline process: Methods, procedures, and participants Support Care Cancer 13 2005 77-79
14. National Comprehensive Cancer Network Guidelines for supportive care, antiemesis http://www.nccn.org/professionals/physician_gls/ f_gu_guidelines.asp?button=I+Agree#care (accessed April 14, 2005).
15. American Society of Health-System Pharmacists ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery Am J Health Syst Pharm 56 1999 729-764
16. Gralla R.J. Osoba D. Kris M.G. et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines J. Clin. Oncol. 1999 17 2971-2994
17. MJ Field KN Lohr Clinical practice guidelines: Directions of a new program 1990 National Academy Press Washington, DC
18. Tunis S.R. Hayward R.S. Wilson M.C. et al. Internists' attitudes about clinical practice guidelines Ann. Intern. Med. 1994 120 956-963
19. Borkowski N.M. Allen W.R. Does attribution theory explain physicians' nonacceptance of clinical practice guidelines? Hosp. Top. 2003 81 9-21
20. Grilli R. Lomas J. Evaluating the message: The relationship between compliance rate and the subject of a practice guideline Med. Care 1994 32 202-213
21. Grol R. Dalhuijsen J. Thomas S. et al. Attributes of clinical guidelines that influence use of guidelines in general practice: Observational study BMJ 1998 317 858-861
22. Foy R. MacLennan G. Grimshaw J. et al. Attributes of clinical recommendations that influence change in practice following audit and feedback J. Clin. Epidemiol. 2002 55 717-722
23. Burgers J. Grol R. Zaat J. et al. Characterics of effective clinical guidelines for general practice Br. J. Gen. Pract. 2003 53 15-19
24. Grol R. Grimshaw J. From best evidence to best practice: Effective implementation of change in patients' care Lancet 2003 362 1225-1230
25. Michie S. Johnston M. Changing clinical behaviour by making guidelines specific BMJ 2004 328 343-345
26. Lomas J. Anderson G.M. Domnick-Pierre K. et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians N. Engl. J. Med. 1989 321 1306-1311
27. Cabana M.D. Rand C.S. Powe N.R. et al. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999 282 1458-1465
28. Grol R. Successes and failures in the implementation of evidence-based guidelines for clincial practice Med. Care 2001 39 SUPPL. 2 46-54
29. The Italian Group for Antiemetic Research Transferability to clinical practice of the results of controlled clinical trials: The case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting Ann. Oncol. 1998 9 759-765
30. Drug Utilization Review Team in Oncology (DURTO) Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy Support Care Cancer 2003 11 785-789
31. Fabi A. Barduagni M. Lauro S. et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study Support Care Cancer 2003 11 156-161
32. Davis D.A. Thomson M.A. Oxman A.D. Haynes R.B. Changing physician performance: A systematic review of the effect of continuing medical education strategies JAMA 1995 249 700-705
33. Bero L.A. Grilli R. Grimshaw J.M. et al. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings BMJ 1998 317 465-468
34. Mazmanian P.E. Davis D.A. Continuing medical education and the physician as a learner: Guide to the evidence JAMA 2002 288 1057-1060
35. Grimshaw J.M. Eccles M.P. Is evidence-based implementation of evidence-based care possible? Med. J. Aust. 2004 180 50-51
36. Nolte M.J. Berkery R. Pizzo B. et al. Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center J. Clin. Oncol. 1998 16 771-778
37. Dranitsaris G. Leung P. Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study Support Care Cancer 2001 9 611-618
38. Mertens W.C Higby D.J. Brown D. et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines J. Clin. Oncol. 2003 21 1373-1378
39. Goldman L. Changing physicians' behavior: The pot and the kettle N. Engl. J. Med. 1990 322 1524-1525
40. Greco P.J. Eisenberg J.M. Changing physicians' practices N. Engl. J. Med. 1993 329 1271-1274